Evidence map›Paper›PMID 26305570›Full record

Trial reportPloS one2015

Effect of Chronic Blood Transfusion on Biomarkers of Coagulation Activation and Thrombin Generation in Sickle Cell Patients at Risk for Stroke.

Hyacinth I Hyacinth, Robert J Adams, Charles S Greenberg, Jenifer H Voeks, Allyson Hill, Jacqueline M Hibbert, Beatrice E Gee

Open access · goldAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Chronic organ failure in adult sickle cell disease.Hematology. American Society of Hematology. Education Program · 2017
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Hyacinth I HyacinthDepartment of Pediatrics Hematology/Oncology, Emory University School of Medicine, Atlanta, GA, United States of America; Stroke Centre, Department of Neurology, Medical University of South Carolina, Charleston, SC, United States of America.
Robert J AdamsStroke Centre, Department of Neurology, Medical University of South Carolina, Charleston, SC, United States of America.
Charles S GreenbergDepartment of Hematology, Medical University of South Carolina, Charleston, SC, United States of America.
Jenifer H VoeksStroke Centre, Department of Neurology, Medical University of South Carolina, Charleston, SC, United States of America.
Allyson HillDepartment of Biology, College of Charleston, Charleston, SC, United States of America.
Jacqueline M HibbertDepartment of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA, United States of America.
Beatrice E GeeDepartment of Pediatrics and Cardiovascular Research Institute, Morehouse School of Medicine, Atlanta, GA, United States of America; Children's Healthcare of Atlanta, Atlanta, GA, United States of America.
Medical University of South Carolina · USChildren's Healthcare of Atlanta · USCollege of Charleston · USMorehouse School of Medicine · US

Funding

Morehouse School of Medicine Center of Excellence Research Endowment ProgramS21MD000101 · NIMHD · MOREHOUSE SCHOOL OF MEDICINE · PI MONTGOMERY-RICE, VALERIE C. · 2001 to 2015
$74.3M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025008 · NCRR · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2007 to 2011
$29.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Research Desogn and Biostatistics CoreU54MD007588 · NIMHD · MOREHOUSE SCHOOL OF MEDICINE · PI MONTGOMERY-RICE, VALERIE C. · 2012 to 2018
$24.8M
WARCEFU54RR026137 · NCRR · MOREHOUSE SCHOOL OF MEDICINE · PI CONERLY HOLLIDAY, RHONDA C · 2009 to 2011
$14.6M
OPTIMIZING STROKE PREVENTION IN SC ANEMIA CHILDRENU01HL052193 · NHLBI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI ADAMS, ROBERT J · 2000 to 2004
$12.8M
Effect of Diet on Inflammation in Sicke Cell MiceR21HL092358 · NHLBI · MOREHOUSE SCHOOL OF MEDICINE · PI HIBBERT, JACQUELINE M · 2009 to 2010
$413k
STROKE PREVENTION TRIAL IN SICKLE CELL ANEMIA (STOP)U10HL052193 · NHLBI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI ADAMS, ROBERT J · 1994 to 2000
$234k
STROKE PREVENTION TRIAL IN SICKLE CELL ANEMIAU10HL052016 · NHLBI · NEW ENGLAND RESEARCH INSTITUTES, INC. · PI BRAMBILLA, DONALD J · 1994 to 2000
$58k
NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1TR000454NCRR NIH HHS 5P20RR0111044NCRR NIH HHS U54 RR026137NCRR NIH HHS UL1 RR025008NHLBI NIH HHS R21 HL092358NHLBI NIH HHS R21HL092358NHLBI NIH HHS U01 HL052193NHLBI NIH HHS U10 HL052016NHLBI NIH HHS U10 HL052193NHLBI NIH HHS U10 HL 52016NHLBI NIH HHS U10 HL 52193NIMHD NIH HHS 8 U54 MD007588-04NIMHD NIH HHS S21 MD000101NIMHD NIH HHS S21 MD000101-05NIMHD NIH HHS U54 MD007588
6 · The paper itself

Abstract

Hypercoagulability in sickle cell disease (SCD) is associated with multiple SCD phenotypes, association with stroke risk has not been well described. We hypothesized that serum levels of biomarkers of coagulation activation correlate with high transcranial Doppler ultrasound velocity and decreases with blood transfusion therapy in SCD patients. Stored serum samples from subjects in the Stroke Prevention in Sickle Cell Anemia (STOP) trial were analyzed using ELISA and protein multiplexing techniques. 40 subjects from each treatment arm (Standard Care [SC] and Transfusion [Tx]) at three time points--baseline, study exit and one year post-trial and 10 each of age matched children with SCD but normal TCD (SNTCD) and with normal hemoglobin (HbAA) were analyzed. At baseline, median vWF, TAT and D-dimer levels were significantly higher among STOP subjects than either HbAA or SNTCD. At study exit, median hemoglobin level was significantly higher while median TCD velocity was significantly lower in Tx compared to SC subjects. Median vWF (409.6 vs. 542.9 μg/ml), TAT (24.8 vs. 40.0 ng/ml) and D-dimer (9.2 vs. 19.1 μg/ml) levels were also significantly lower in the Tx compared to the SC group at study exit. Blood levels of biomarkers coagulation activation/thrombin generation correlated positively with TCD velocity and negatively with number of blood transfusions. Biomarkers of coagulation activation/thrombin generation were significantly elevated in children with SCD, at high risk for stroke. Reduction in levels of these biomarkers correlated with reduction in stroke risk (lower TCD velocity), indicating a possible role for hypercoagulation in SCD associated stroke.

Indexed as

Blood CoagulationBlood TransfusionAnemia, Sickle CellAntithrombin IIIBiomarkersChildFibrin Fibrinogen Degradation ProductsHumansPeptide HydrolasesRisk FactorsStrokeThrombinUltrasonography, Doppler, Transcranialvon Willebrand FactorAntithrombin IIIantithrombin III-protease complexBiomarkersFibrin Fibrinogen Degradation Productsfibrin fragment DPeptide HydrolasesThrombinvon Willebrand Factor

Identifiers

PMID26305570
PMCPMC4549306
OpenAlexW2107778733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.